Prednisone - Comprehensive Research Paper

Document Information

• Paper Number: 49 of 76
• Category: Corticosteroids - Glucocorticoids
• Last Updated: 2025-12-26
• Status: FDA-APPROVED (since 1955)

1. Summary

Prednisone is a synthetic glucocorticoid medication that serves as a cornerstone in the management of inflammatory, autoimmune, allergic, and neoplastic conditions. As a prodrug, prednisone requires hepatic conversion to its active metabolite, prednisolone, to exert its pharmacological effects. First granted FDA approval on February 21, 1955, prednisone remains one of the most widely prescribed corticosteroids worldwide due to its intermediate potency, oral bioavailability, and broad therapeutic applications.

Prednisone functions primarily through glucocorticoid receptor activation, modulating gene transcription to reduce inflammation and suppress immune responses. At higher doses, it also exhibits mineralocorticoid activity, affecting sodium and potassium balance. The drug's anti-inflammatory potency is approximately 4 times that of hydrocortisone, with an equivalent dose ratio of 5 mg prednisone to 20 mg hydrocortisone.

Clinical Applications: Prednisone is indicated for an exceptionally wide range of conditions including:

• Endocrine disorders (adrenal insufficiency, congenital adrenal hyperplasia)
• Rheumatic diseases (rheumatoid arthritis, lupus, polymyalgia rheumatica)
• Allergic conditions (severe allergic reactions, asthma exacerbations)
• Dermatologic diseases (pemphigus, severe dermatitis)
• Pulmonary diseases (COPD exacerbations, sarcoidosis)
• Hematologic disorders (autoimmune hemolytic anemia, ITP)
• Neoplastic diseases (as part of chemotherapy regimens)
• Organ transplantation (immunosuppression)
• Inflammatory bowel disease
• Nephrotic syndrome

Key Characteristics:

• Generic Name: Prednisone
• Brand Names: Deltasone, Rayos (delayed-release), Prednisone Intensol, others
• FDA Approval: February 21, 1955
• Drug Class: Synthetic glucocorticoid corticosteroid
• Prodrug Status: Yes - requires hepatic conversion to prednisolone
• Potency Ratio: 4:1 anti-inflammatory vs. hydrocortisone
• Mineralocorticoid Activity: Low (0.8 relative to hydrocortisone)
• Half-Life: Plasma 60 minutes; biological 12-36 hours (intermediate-acting)
• Controlled Substance: No
• Pregnancy Category: C (Category D for delayed-release)
• Available Formulations: Immediate-release tablets, delayed-release tablets, oral solution

Critical Safety Considerations:

• Long-term use causes significant adverse effects including osteoporosis, adrenal suppression, diabetes, and immunosuppression
• Must be tapered gradually after prolonged use (risk of adrenal crisis)
• Contraindicated in systemic fungal infections
• Significant drug interaction profile
• Monitoring required for bone health, blood glucose, blood pressure, and ocular effects

Goal Relevance:

• Manage chronic inflammation and reduce pain associated with rheumatoid arthritis or lupus.
• Control severe asthma attacks and improve breathing in individuals with respiratory conditions.
• Alleviate symptoms of autoimmune diseases like multiple sclerosis or inflammatory bowel disease.
• Support recovery and prevent organ rejection after a transplant.
• Treat severe allergic reactions and provide relief from persistent skin rashes or dermatitis.
• Help manage blood disorders such as autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura (ITP).
• Assist in reducing inflammation and pain in conditions like polymyalgia rheumatica.
• Provide support during chemotherapy by managing inflammation and immune responses.

2. Mechanism of Action

Prednisone exerts its effects through glucocorticoid receptor-mediated mechanisms following hepatic conversion to its active form, prednisolone. The drug modulates inflammatory and immune responses at multiple levels.

Prodrug Activation

Hepatic Conversion:

• Prednisone is a biologically inactive prodrug
• Converted to prednisolone by 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the liver
• Conversion is approximately 80-100% efficient in healthy individuals
• Patients with liver dysfunction may have reduced conversion efficiency
• Prednisolone is the pharmacologically active compound

Genomic Mechanisms (Primary)

Glucocorticoid Receptor Activation:

1. Prednisolone (active form) crosses cell membranes due to lipophilicity
2. Binds to cytoplasmic glucocorticoid receptors (GR-α)
3. Receptor-ligand complex dissociates from heat shock proteins (Hsp90, Hsp70)
4. Complex translocates to the nucleus
5. Binds to glucocorticoid response elements (GREs) on DNA
6. Modulates gene transcription (transactivation and transrepression)

Transactivation (Gene Activation):

• Increases expression of anti-inflammatory proteins:
  • Lipocortin-1 (annexin A1) - inhibits phospholipase A2
  • IκBα - inhibits NF-κB signaling
  • MAPK phosphatase-1 - deactivates inflammatory MAPK pathways
  • IL-10 - anti-inflammatory cytokine
  • β2-adrenergic receptors - enhances bronchodilator response

Transrepression (Gene Suppression):

• Decreases expression of pro-inflammatory mediators:
  • Cytokines: IL-1β, IL-2, IL-6, TNF-α, IFN-γ
  • Chemokines: IL-8, RANTES, MCP-1
  • Adhesion molecules: ICAM-1, VCAM-1, E-selectin
  • Enzymes: COX-2, iNOS, phospholipase A2
  • Prostaglandins and leukotrienes

NF-κB Inhibition:

• Direct interaction with NF-κB transcription factor
• Prevents NF-κB binding to DNA
• Induces IκBα expression (sequesters NF-κB in cytoplasm)
• Major mechanism for anti-inflammatory effects

Non-Genomic Mechanisms (Rapid)

Membrane Effects:

• Rapid onset (seconds to minutes) effects independent of gene transcription
• Membrane-bound glucocorticoid receptors
• Modulation of ion channels
• Effects on cellular signaling pathways
• Clinically relevant in high-dose/pulse therapy

Mitochondrial Effects:

• Influences mitochondrial membrane potential
• Modulates oxidative phosphorylation
• Contributes to apoptosis in certain cell types (lymphocytes)

Immunosuppressive Effects

Lymphocyte Effects:

• Induces lymphocyte apoptosis (especially T cells)
• Redistributes lymphocytes from circulation to lymphoid tissue
• Decreases lymphocyte proliferation
• Inhibits cytokine production

Monocyte/Macrophage Effects:

• Reduces monocyte migration
• Inhibits antigen presentation
• Decreases phagocytosis at high doses
• Suppresses cytokine release

Neutrophil Effects:

• Increases circulating neutrophils (demargination)
• Impairs neutrophil migration to inflammatory sites
• Reduces neutrophil adhesion to endothelium

Eosinophil Effects:

• Induces eosinophil apoptosis
• Reduces eosinophil recruitment
• Decreases circulating eosinophil counts

Metabolic Effects

Carbohydrate Metabolism:

• Increases hepatic gluconeogenesis
• Decreases peripheral glucose utilization
• Causes insulin resistance
• Leads to hyperglycemia (diabetogenic effect)

Protein Metabolism:

• Increases protein catabolism
• Decreases protein synthesis in muscle
• Causes muscle wasting with prolonged use
• Negative nitrogen balance

Lipid Metabolism:

• Promotes lipolysis
• Causes fat redistribution (central obesity)
• May increase total cholesterol and triglycerides

Bone Metabolism:

• Decreases intestinal calcium absorption
• Increases renal calcium excretion
• Inhibits osteoblast activity
• Leads to osteoporosis with prolonged use

Mineralocorticoid Effects

At Higher Doses:

• Activates mineralocorticoid receptors
• Increases sodium retention
• Increases potassium excretion
• Causes fluid retention and hypertension
• Less pronounced than hydrocortisone or cortisone

3. FDA-Approved Indications

Prednisone is FDA-approved for a remarkably broad range of conditions, reflecting the fundamental role of glucocorticoids in modulating inflammation and immune responses.

Endocrine Disorders

Primary Indications:

• Primary adrenocortical insufficiency (Addison's disease) - as replacement therapy
• Secondary adrenocortical insufficiency
• Congenital adrenal hyperplasia
• Hypercalcemia associated with cancer
• Nonsuppurative thyroiditis

Rheumatic Disorders

Primary Indications:

• Rheumatoid arthritis (including juvenile)
• Psoriatic arthritis
• Ankylosing spondylitis
• Acute and subacute bursitis
• Acute nonspecific tenosynovitis
• Acute gouty arthritis
• Post-traumatic osteoarthritis
• Synovitis of osteoarthritis
• Epicondylitis
• Systemic lupus erythematosus
• Systemic dermatomyositis (polymyositis)
• Polymyalgia rheumatica
• Giant cell arteritis

Dermatologic Diseases

Primary Indications:

• Pemphigus
• Bullous dermatitis herpetiformis
• Severe erythema multiforme (Stevens-Johnson syndrome)
• Exfoliative dermatitis
• Mycosis fungoides
• Severe psoriasis
• Severe seborrheic dermatitis
• Atopic dermatitis (severe)

Allergic States

Primary Indications:

• Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment
• Bronchial asthma
• Seasonal or perennial allergic rhinitis
• Contact dermatitis
• Atopic dermatitis
• Serum sickness
• Drug hypersensitivity reactions
• Angioedema

Ophthalmic Diseases

Primary Indications:

• Severe acute and chronic allergic and inflammatory processes involving the eye
• Allergic conjunctivitis
• Keratitis
• Allergic corneal marginal ulcers
• Herpes zoster ophthalmicus
• Iritis and iridocyclitis
• Chorioretinitis
• Anterior segment inflammation
• Diffuse posterior uveitis and choroiditis
• Optic neuritis
• Sympathetic ophthalmia

Respiratory Diseases

Primary Indications:

• Symptomatic sarcoidosis
• Loeffler's syndrome not manageable by other means
• Berylliosis
• Fulminating or disseminated pulmonary tuberculosis (with appropriate antituberculous chemotherapy)
• Aspiration pneumonitis
• COPD exacerbations
• Asthma exacerbations
• Acute respiratory distress syndrome

Hematologic Disorders

Primary Indications:

• Idiopathic thrombocytopenic purpura (ITP) in adults
• Secondary thrombocytopenia in adults
• Acquired (autoimmune) hemolytic anemia
• Erythroblastopenia (RBC anemia)
• Congenital (erythroid) hypoplastic anemia
• Diamond-Blackfan anemia

Neoplastic Diseases

Primary Indications:

• Palliative management of leukemias and lymphomas in adults
• Acute leukemia of childhood
• Part of combination chemotherapy regimens for:
  • Multiple myeloma
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Chronic lymphocytic leukemia

Gastrointestinal Diseases

Primary Indications:

• Ulcerative colitis
• Regional enteritis (Crohn's disease)
• Intractable sprue
• Acute hepatic failure

Renal Diseases

Primary Indications:

• Nephrotic syndrome (idiopathic or due to lupus)
• To induce diuresis or remission of proteinuria in nephrotic syndrome without uremia

Nervous System

Primary Indications:

• Acute exacerbations of multiple sclerosis
• Cerebral edema associated with primary or metastatic brain tumor
• Craniotomy or head injury
• Tuberculous meningitis with subarachnoid block or impending block (with appropriate antituberculous chemotherapy)

Organ Transplantation

Primary Indication:

• Prevention and treatment of organ transplant rejection (in combination with other immunosuppressants)

Miscellaneous

Additional Indications:

• Trichinosis with neurologic or myocardial involvement
• COVID-19 (hospitalized patients requiring supplemental oxygen - based on RECOVERY trial data)

4. Dosing and Administration

Prednisone dosing is highly variable and must be individualized based on the specific condition being treated, disease severity, patient factors, and response to therapy. The goal is always to use the lowest effective dose for the shortest duration possible.

Dosage Forms

Immediate-Release Tablets:

• 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg

Delayed-Release Tablets (Rayos):

• 1 mg, 2 mg, 5 mg

Oral Solution:

• 5 mg/5 mL (Prednisone Intensol: 5 mg/mL concentrate)

General Dosing Principles

Initial Dosing:

• Dose varies enormously: 5 mg/day to 60-80 mg/day or higher
• Initial dose based on severity of condition
• High-dose regimens may use up to 1-2 mg/kg/day

Maintenance Dosing:

• Reduce to lowest effective dose
• Alternate-day therapy may minimize adrenal suppression
• Goal: <10 mg/day for long-term use when possible

Tapering:

• Required after >2-3 weeks of therapy
• Gradual reduction to prevent adrenal insufficiency
• Typical taper: Reduce by 10-20% every 1-2 weeks
• Slower tapering for longer duration of therapy

Condition-Specific Dosing

Rheumatoid Arthritis:

• Initial: 5-10 mg/day
• May use higher doses (20-60 mg/day) for flares
• Maintenance: Lowest effective dose, ideally <7.5 mg/day
• Goal: Taper to discontinuation when possible

Systemic Lupus Erythematosus:

• Mild disease: 10-20 mg/day
• Moderate disease: 20-40 mg/day
• Severe/organ-threatening: 1-2 mg/kg/day (up to 60-80 mg/day)
• Maintenance: Taper to lowest effective dose

Asthma Exacerbation:

• Adults: 40-60 mg/day for 5-10 days
• Children: 1-2 mg/kg/day (max 60 mg) for 3-10 days
• Short courses do not require tapering

COPD Exacerbation:

• 40 mg/day for 5 days (per GOLD guidelines)
• Short course does not require tapering

Allergic Reactions (Severe):

• 40-60 mg/day initially
• Taper over 1-2 weeks
• May not require tapering if <1-2 weeks

Inflammatory Bowel Disease:

• Moderate-severe: 40-60 mg/day
• Taper over 8-12 weeks to discontinuation
• Bridge to steroid-sparing agents

Multiple Sclerosis (Acute Exacerbation):

• High-dose pulse: 1000 mg IV methylprednisolone for 3-5 days
• May follow with oral prednisone taper
• Oral equivalent: 60-80 mg/day with taper

Polymyalgia Rheumatica:

• Initial: 12.5-25 mg/day
• Response typically rapid (dramatic improvement in 24-72 hours)
• Slow taper over 1-2 years
• Maintenance: 5-10 mg/day

Giant Cell Arteritis:

• Initial: 40-60 mg/day
• Higher doses if visual symptoms present
• Slow taper over 1-2 years
• Tocilizumab may be added as steroid-sparing agent

Nephrotic Syndrome (Adults):

• Initial: 1 mg/kg/day (max 80 mg/day)
• Continue until remission (usually 4-16 weeks)
• Taper over several months

Organ Transplant:

• Part of multi-drug immunosuppression regimen
• Initial: 0.5-2 mg/kg/day
• Rapid taper to maintenance dose
• Maintenance: 5-10 mg/day (often tapered to discontinuation)

Delayed-Release Tablets (Rayos)

Mechanism:

• Inactive shell delays drug release by ~4 hours
• Designed for bedtime dosing to address morning symptoms

Dosing:

• Same mg doses as immediate-release
• Take at bedtime with food
• Drug release occurs in early morning

Indication:

• Rheumatoid arthritis
• Conditions with morning stiffness or circadian symptom pattern

Administration Guidelines

Timing:

• Usually taken once daily in the morning (to mimic cortisol rhythm)
• Divided doses may be used for some conditions
• Rayos: Taken at bedtime

With Food:

• Take with food to reduce GI upset
• Food does not significantly affect absorption

Alternate-Day Therapy:

• Double the daily dose given every other morning
• May reduce HPA axis suppression and adverse effects
• Not appropriate for all conditions

Tapering Guidelines

When to Taper:

• Any course >2-3 weeks duration
• Higher doses or longer durations require slower tapers

General Taper Approach:

• Short course (<3 weeks): May not need taper or brief taper
• Moderate course (3-4 weeks): Reduce by 5-10 mg every 3-7 days
• Long-term therapy: Reduce by 1-2.5 mg every 2-4 weeks

Stress Dosing:

• Patients on long-term prednisone may need increased doses during:
  • Surgery
  • Severe illness
  • Trauma
• "Stress dose" protocols vary by institution

5. Pharmacokinetics

Understanding prednisone pharmacokinetics is essential for optimal dosing, particularly given its prodrug nature requiring hepatic activation.

Absorption

Oral Bioavailability:

• Immediate-release: Well absorbed; bioavailability ~70-80%
• Delayed-release (Rayos): Similar bioavailability with ~4-hour delay
• Peak plasma concentration (Tmax): 1-2 hours (immediate-release)
• Delayed-release Tmax: 6-6.5 hours (designed for bedtime dosing)

Food Effects:

• Food may slow but does not significantly reduce absorption
• Delayed-release should be taken with food (increases absorption)

Dose Proportionality:

• Pharmacokinetics are dose-dependent
• Higher doses show increased volume of distribution and clearance
• Non-linear protein binding contributes to dose-dependency

Distribution

Volume of Distribution:

• Approximately 0.4-1 L/kg
• Increases with higher doses (due to protein binding saturation)
• Widely distributed to tissues

Protein Binding:

• Prednisone: ~70% bound (primarily albumin)
• Prednisolone: ~90-95% bound
  • Corticosteroid-binding globulin (transcortin): High affinity, low capacity
  • Albumin: Lower affinity, high capacity
• Free (active) fraction: ~5-10%
• Binding is saturable - free fraction increases at higher doses

Tissue Distribution:

• Crosses blood-brain barrier
• Crosses placenta
• Enters breast milk in low concentrations
• Distributes to inflammatory sites

Metabolism

Prodrug Activation:

• Prednisone → Prednisolone (active form)
• Enzyme: 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
• Location: Primarily liver
• Efficiency: Near complete in healthy individuals (~80-100%)

Impaired Conversion:

• Severe liver disease may reduce conversion
• Consider using prednisolone directly in hepatic impairment
• Some data suggest conversion remains adequate in mild-moderate liver disease

Further Metabolism:

• Prednisolone undergoes hepatic metabolism
• CYP3A4 involvement in some metabolic pathways
• Multiple metabolites formed
• Enterohepatic circulation occurs

Elimination

Plasma Half-Life:

• Prednisone: ~60 minutes (range 2-3 hours)
• Prednisolone: ~2-4 hours (range 2.1-3.5 hours)
• Intersubject variability is substantial

Biological Half-Life:

• Duration of action: 12-36 hours
• Classified as intermediate-acting glucocorticoid
• Allows once-daily dosing for most indications

Excretion:

• Renal elimination of metabolites
• <1% excreted unchanged in urine
• Fecal elimination via bile

Special Population Pharmacokinetics

Hepatic Impairment:

• Prednisone conversion to prednisolone may be impaired
• Hypoalbuminemia increases free drug fraction
• Half-life may be prolonged
• Consider using prednisolone directly

Renal Impairment:

• Minimal effect on pharmacokinetics
• No dose adjustment typically required
• May have increased sensitivity due to hypoalbuminemia

Pediatric:

• Faster clearance in children
• Shorter half-life
• Weight-based dosing used

Geriatric:

• May have reduced clearance
• Increased sensitivity to adverse effects
• Start with lower doses

Obesity:

• Ideal body weight often used for dosing
• Obesity may affect distribution

Drug Interactions Affecting Pharmacokinetics

Increased Clearance (CYP3A4 Inducers):

• Rifampin (most significant)
• Phenytoin
• Phenobarbital
• Carbamazepine
• May require 50-100% dose increase

Decreased Clearance:

• Ketoconazole and other CYP3A4 inhibitors
• Oral contraceptives (increase transcortin levels)
• May require dose reduction

Altered Protein Binding:

• Hypoalbuminemia increases free drug
• Oral contraceptives increase transcortin (more bound drug)

6. Side Effects and Adverse Reactions

Prednisone adverse effects are both dose-dependent and duration-dependent. Short-term use at low to moderate doses is generally well-tolerated, while long-term therapy causes significant cumulative toxicity affecting virtually every organ system.

Short-Term Side Effects (Common)

Metabolic/Endocrine:

• Increased appetite and weight gain
• Fluid retention (edema)
• Hyperglycemia (new-onset or worsening diabetes)
• Hypokalemia

Neuropsychiatric:

• Insomnia (very common)
• Mood changes (euphoria, irritability)
• Anxiety and restlessness
• Difficulty concentrating

Gastrointestinal:

• Dyspepsia and heartburn
• Increased appetite
• Nausea
• Abdominal bloating

Cardiovascular:

• Hypertension
• Fluid retention

Dermatologic:

• Facial flushing
• Acne
• Increased sweating

Long-Term Side Effects (Duration >3 Months)

Musculoskeletal:

• Osteoporosis: Most significant long-term risk
  • Bone loss begins within first few months
  • 7-fold increase in hip fractures with 10 mg/day for >90 days
  • 17-fold increase in vertebral fractures
  • Even 5 mg/day affects bone metabolism
  • Risk present even at 2.5 mg/day (2x fracture risk within 3 months)
• Osteonecrosis (Avascular Necrosis):
  • Particularly femoral head
  • Can occur with relatively short courses
  • May require joint replacement
• Myopathy:
  • Proximal muscle weakness
  • Affects shoulder and hip girdle muscles
  • Reversible with dose reduction

Endocrine:

• Adrenal Suppression:
  • HPA axis suppression occurs with prolonged use
  • Risk of adrenal insufficiency if abruptly discontinued
  • May persist months after discontinuation
  • Requires stress dosing during illness/surgery
• Cushing's Syndrome (Iatrogenic):
  • Moon facies
  • Buffalo hump (dorsocervical fat pad)
  • Central obesity
  • Striae (purple)
  • Skin atrophy and bruising
• Diabetes:
  • New-onset diabetes
  • Worsening glycemic control in existing diabetics
  • May require insulin initiation

Cardiovascular:

• Hypertension
• Increased cardiovascular disease risk
• Accelerated atherosclerosis
• Fluid retention and edema

Ophthalmologic:

• Cataracts:
  • Posterior subcapsular cataracts
  • Risk increases with dose and duration
• Glaucoma:
  • Increased intraocular pressure
  • May require treatment or monitoring
• Central Serous Chorioretinopathy:
  • Rare but significant

Dermatologic:

• Skin atrophy and fragility
• Easy bruising
• Poor wound healing
• Striae (stretch marks)
• Hirsutism
• Acne

Gastrointestinal:

• Peptic ulcer disease (controversial - risk may be lower than previously thought)
• Gastritis
• Pancreatitis (rare)
• Increased risk when combined with NSAIDs

Immunologic:

• Increased Infection Risk:
  • Opportunistic infections
  • Reactivation of latent infections (TB, hepatitis B)
  • Masked infection symptoms
  • Impaired wound healing
• Immunosuppression:
  • Dose-dependent effect

  • 20 mg/day considered significantly immunosuppressive

Neuropsychiatric:

• Depression
• Mania and psychosis (especially at high doses)
• Cognitive impairment
• Memory problems
• Severe mood swings

Other:

• Growth suppression in children
• Menstrual irregularities
• Lipodystrophy (fat redistribution)
• Hypernatremia and hypokalemia

Dose-Response Patterns

Linear Dose-Response Effects:

• Frequency increases proportionally with dose
• Examples: Weight gain, insomnia

Threshold Dose Effects:

• Minimal risk below certain dose; rapid increase above threshold
• Weight gain, epistaxis: >5 mg/day threshold
• Glaucoma, depression, hypertension: >7.5 mg/day threshold

Withdrawal Symptoms

Adrenal Insufficiency:

• Fatigue, weakness
• Hypotension
• Hypoglycemia
• Nausea, vomiting
• Can be life-threatening (adrenal crisis)

Steroid Withdrawal Syndrome:

• Joint and muscle pain
• Fatigue
• Depression
• May occur even with appropriate taper

7. Drug Interactions

Prednisone has extensive drug interactions affecting efficacy and safety of both prednisone and concomitant medications.

Contraindicated Combinations

Mifepristone:

• Contraindicated in patients on chronic corticosteroid therapy
• Mifepristone is a glucocorticoid receptor antagonist
• Would negate therapeutic effects

Live Vaccines:

• Avoid live vaccines in patients on immunosuppressive doses
• Risk of disseminated vaccine infection
• Wait ≥3 months after stopping high-dose therapy
• Inactivated vaccines may be given (though response may be blunted)

Significant Drug Interactions

CYP3A4 Inducers (Decrease Prednisone Effect):

CYP3A4 Inhibitors (Increase Prednisone Effect):

Hormonal Interactions:

Pharmacodynamic Interactions

Anticoagulants:

• Warfarin: Variable effect on INR (may increase or decrease)
• Monitor INR closely when initiating or adjusting prednisone
• May need warfarin dose adjustment

Diabetes Medications:

• Insulin: Prednisone causes hyperglycemia; may need increased insulin doses
• Oral hypoglycemics: May need dose increases
• Monitor blood glucose closely

NSAIDs:

• Increased GI bleeding risk (synergistic)
• Both cause GI mucosal injury
• Use GI protection if combination necessary

Diuretics:

• Loop and thiazide diuretics: Additive hypokalemia
• Monitor potassium levels
• Consider potassium supplementation

Cardiac Glycosides (Digoxin):

• Hypokalemia from prednisone increases digoxin toxicity risk
• Monitor potassium and digoxin levels

Fluoroquinolones:

• Increased tendon rupture risk (synergistic)
• Particularly in elderly patients
• Caution with concomitant use

Anticholinesterases:

• Corticosteroids may produce severe weakness in myasthenia gravis patients
• Particularly during initiation of corticosteroid therapy
• Use with caution

Antihypertensives:

• Prednisone causes sodium retention and hypertension
• May reduce efficacy of antihypertensives
• May need to increase antihypertensive doses

Immunosuppressants:

• Additive immunosuppression
• Increased infection risk
• Common in transplant patients (expected)

Other Interactions

Aspirin:

• Increases aspirin clearance
• May reduce aspirin levels
• Discontinuation of prednisone may increase aspirin levels (toxicity risk)

Cholestyramine:

• May reduce prednisone absorption
• Separate administration by 2-4 hours

Antacids:

• May reduce prednisone absorption slightly
• Usually not clinically significant

Amphotericin B:

• Additive hypokalemia
• Monitor potassium closely

Cyclosporine:

• Mutual inhibition of metabolism
• Both levels may be affected
• Common combination in transplantation

8. Contraindications

Absolute Contraindications

Systemic Fungal Infections:

• The only absolute contraindication listed in prescribing information
• Immunosuppressive effects can lead to disseminated fungal disease
• Must treat fungal infection before initiating therapy if life-threatening condition requires prednisone

Hypersensitivity:

• True hypersensitivity to prednisone or formulation components
• Extremely rare
• May cross-react with other corticosteroids

Relative Contraindications (Use with Extreme Caution)

Active Infections:

• Untreated bacterial infections
• Active tuberculosis (unless on appropriate anti-TB therapy)
• Systemic viral infections (herpes simplex, varicella, measles)
• Parasitic infections (Strongyloides - risk of hyperinfection syndrome)
• Latent infections (screen for TB, hepatitis B before immunosuppressive doses)

Psychiatric Disorders:

• Active psychosis
• Severe depression
• History of steroid-induced psychosis
• Caution: Steroids can precipitate or worsen psychiatric symptoms

Gastrointestinal:

• Active peptic ulcer disease
• Diverticulitis
• Fresh intestinal anastomoses
• GI perforation risk

Cardiovascular:

• Uncontrolled hypertension
• Recent myocardial infarction
• Congestive heart failure (fluid retention)

Endocrine:

• Diabetes mellitus (will worsen glycemic control)
• Cushing's syndrome
• Adrenal insufficiency (requires replacement dosing, not pharmacologic doses)

Ophthalmologic:

• Ocular herpes simplex (risk of corneal perforation)
• Uncontrolled glaucoma

Musculoskeletal:

• Severe osteoporosis
• Recent fractures

Other:

• Myasthenia gravis (risk of acute exacerbation, especially with initiation)
• Kaposi's sarcoma (may promote growth)
• Thromboembolic disorders (controversial)

Warnings and Precautions

HPA Axis Suppression:

• May occur with any dose if duration >2-3 weeks
• Avoid abrupt discontinuation
• Stress dosing may be needed during illness/surgery for up to 1 year after discontinuation

Immunosuppression:

• Increased susceptibility to infections
• Masks signs and symptoms of infection
• Pre-existing infections may be exacerbated
• Screen for latent TB before high-dose/prolonged therapy

Vaccination:

• Avoid live vaccines during immunosuppressive therapy
• Response to inactivated vaccines may be diminished

Behavioral/Mood Disturbances:

• Can cause mood swings, depression, euphoria, psychosis
• More common at higher doses
• May require psychiatric intervention

Pediatric Growth:

• Chronic use suppresses growth
• Use lowest effective dose
• Monitor growth velocity

9. Special Populations

Pregnancy

FDA Category: C (immediate-release); D (delayed-release/Rayos)

Placental Transfer:

• Prednisone and prednisolone cross the placenta
• Placental 11β-HSD2 inactivates some prednisolone
• Fetal exposure is approximately 10% of maternal levels
• Less placental transfer than dexamethasone or betamethasone

Potential Risks:

First Trimester:

• Historical concern for cleft lip/palate (OR ~1.3-3)
• Risk appears small: increases from 1/1000 to 3-5/1000
• Newer studies question this association
• Risk-benefit assessment needed

Throughout Pregnancy:

• Preterm delivery (long-term use)
• Low birth weight
• Intrauterine growth restriction (high doses)
• Gestational diabetes (worsened glycemic control)
• Preeclampsia risk may be altered
• Premature rupture of membranes

Neonatal:

• Adrenal insufficiency in newborn (with high maternal doses)
• Observe for signs of hypoadrenalism

When Benefits Outweigh Risks:

• Many conditions requiring prednisone are more dangerous untreated
• Rheumatoid arthritis, lupus, asthma - treatment often continued
• Use lowest effective dose
• Prednisolone may be preferred (doesn't require hepatic conversion)

Antenatal Corticosteroids:

• Short-course for fetal lung maturity is well-established
• Betamethasone or dexamethasone preferred for this indication
• Different from chronic prednisone therapy

Lactation

Breast Milk Excretion:

• Prednisone and prednisolone are excreted in breast milk
• Milk concentrations are low
• Infant receives ~5-25% of maternal weight-adjusted dose
• Generally considered compatible with breastfeeding

Recommendations:

• Low to moderate doses are generally safe
• At doses >20 mg/day, consider waiting 4 hours after dose to breastfeed
• Monitor infant for growth, feeding issues
• AAP considers compatible with breastfeeding

Pediatric

Approved Uses:

• Many indications are approved in children
• Dosing typically weight-based (mg/kg)

Special Considerations:

• Growth Suppression: Major concern with chronic use
  • Monitor height velocity
  • Use lowest effective dose
  • Consider alternate-day therapy
• Increased susceptibility to infections
• May affect development
• Behavioral changes more pronounced

Dosing:

• Asthma exacerbation: 1-2 mg/kg/day (max 60 mg)
• Nephrotic syndrome: 2 mg/kg/day (max 60 mg)
• Weight-based for most indications

Geriatric

Increased Risks:

• Higher susceptibility to adverse effects
• More pronounced bone loss (already at osteoporosis risk)
• Increased infection risk
• Greater glucose intolerance
• Higher cardiovascular risk
• More cognitive effects

Recommendations:

• Start at lower doses
• Closer monitoring required
• Bone protection essential (calcium, vitamin D, bisphosphonates)
• Monitor blood pressure and glucose
• Assess for delirium during high-dose therapy

Hepatic Impairment

Considerations:

• Prednisone is a prodrug requiring hepatic conversion
• Severe liver disease may impair conversion to prednisolone
• Hypoalbuminemia increases free drug fraction

Recommendations:

• Consider using prednisolone directly instead of prednisone
• Start with lower doses
• Monitor for increased effect (due to higher free fraction)
• Mild-moderate impairment: Conversion usually adequate

Renal Impairment

Considerations:

• Minimal effect on prednisone pharmacokinetics
• No routine dose adjustment required
• Hypoalbuminemia in nephrotic syndrome increases free drug

Recommendations:

• Standard dosing generally appropriate
• Monitor for edema and fluid overload
• Be aware of infection risk (especially in immunocompromised renal patients)

Diabetes Mellitus

Impact:

• Prednisone significantly worsens glycemic control
• Increases hepatic gluconeogenesis
• Causes peripheral insulin resistance
• May precipitate diabetes in predisposed patients

Management:

• Close blood glucose monitoring
• May need to initiate or increase insulin
• Adjust oral hypoglycemics
• Consider sliding-scale insulin for hospital patients
• Glucose effects correlate with timing (peak effect 4-8 hours post-dose)

10. Monitoring Parameters

Appropriate monitoring is essential for patients on prednisone, particularly those on long-term therapy.

Baseline Assessment

Before Initiating Therapy (Especially Long-Term):

1. Blood Glucose: Fasting glucose or HbA1c
2. Blood Pressure: Baseline measurement
3. Bone Density (DEXA): If expected duration >3 months
4. Ophthalmologic Exam: Baseline IOP and lens examination
5. Electrolytes: Potassium, sodium
6. Lipid Panel: Baseline lipid profile
7. Weight: Baseline measurement
8. Height (Children): Baseline for growth monitoring
9. TB Screening: PPD or IGRA if immunosuppressive doses planned
10. Hepatitis B Serology: If immunosuppressive doses (risk of reactivation)

Ongoing Monitoring

Every Visit:

• Blood pressure
• Weight
• Signs/symptoms of infection
• Mental status/mood changes
• Glycemic control (symptoms of hyperglycemia)
• Cushing's features

Periodic Laboratory Tests:

Long-Term Monitoring:

Specific Monitoring Situations

Bone Health (Critical for Long-Term Use):

• DEXA scan at baseline and every 1-2 years
• Implement bone protection for all patients on ≥3 months therapy:
  • Calcium: 1000-1200 mg/day
  • Vitamin D: 600-800 IU/day (or more if deficient)
  • Consider bisphosphonate if T-score <-1.0 or high fracture risk
• Fall risk assessment in elderly

Glucose Monitoring:

• More frequent in diabetics
• Self-monitoring blood glucose during high-dose therapy
• HbA1c every 3 months if glycemic control concerns

Infection Surveillance:

• Low threshold for investigating symptoms
• Remember symptoms may be masked
• Monitor for opportunistic infections (especially if high-dose/long-term)
• Annual influenza vaccination (inactivated)
• Pneumococcal vaccination

Adrenal Function:

• Consider morning cortisol after prolonged therapy
• ACTH stimulation test if adrenal insufficiency suspected
• Assess before discontinuation of long-term therapy

Ophthalmologic:

• Annual eye exam (or more frequent with symptoms)
• Intraocular pressure monitoring
• Report visual changes immediately

Cardiovascular:

• Regular blood pressure monitoring
• ECG if arrhythmia symptoms
• Lipid management

Signs/Symptoms Requiring Immediate Attention

• Fever or signs of infection
• Significant mood changes or psychosis
• Severe abdominal pain (GI perforation, pancreatitis)
• Visual changes (glaucoma, cataracts)
• Bone pain (fracture, osteonecrosis)
• Symptoms of adrenal insufficiency during tapering

Tapering Monitoring

• Symptoms of adrenal insufficiency
• Disease flare
• Steroid withdrawal syndrome
• Consider morning cortisol before final discontinuation
• Educate on stress dosing needs

11. Cost and Availability

Current US Availability

Prednisone is widely available in the United States as a generic medication, making it one of the most affordable prescription drugs.

Formulations Available

Immediate-Release Tablets (Generic):

• 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg tablets
• Multiple generic manufacturers

Delayed-Release Tablets (Brand and Generic):

• Rayos (brand): 1 mg, 2 mg, 5 mg
• Generic delayed-release now available

Oral Solution:

• 5 mg/5 mL (1 mg/mL) oral solution
• Prednisone Intensol: 5 mg/mL concentrate (more concentrated)

Pricing

Generic Immediate-Release Tablets:

Delayed-Release (Rayos):

Note: Generic delayed-release now available at lower cost (~$200-400/month)

Oral Solution:

• 5 mg/5 mL: $10-30 per 120 mL bottle
• Prednisone Intensol: $50-100 per 30 mL bottle

Insurance Coverage

Generic Prednisone:

• Widely covered with minimal or no copay
• On $4 generic lists at many pharmacies
• Tier 1 on virtually all formularies
• Prior authorization rarely required

Rayos (Delayed-Release):

• Higher tier (Tier 3 or specialty)
• May require prior authorization
• Step therapy (trial of generic first) often required
• Patient assistance programs available

Manufacturer and Supply

Generic Manufacturers:

• Multiple manufacturers (Teva, Mylan, Sandoz, others)
• Abundant supply; shortages rare
• Competitive pricing

Brand Rayos:

• Manufactured by Horizon Therapeutics
• Patient assistance program available for eligible patients

Access Programs

Manufacturer Savings Programs:

• Horizon Patient Assistance (for Rayos)
• Various pharmacy discount programs

Discount Programs:

• GoodRx, RxSaver, SingleCare: May reduce cash prices further
• $4 generic programs at major retail pharmacies
• Mark Cuban Cost Plus Drugs: Low-cost options available

International Availability

Worldwide:

• Prednisone is available globally
• Generic in most countries
• On WHO Essential Medicines List
• Various brand names internationally:
  • Deltasone, Meticorten, Sterapred (historical US)
  • Decortin (Germany)
  • Various others worldwide

12. Clinical Evidence Summary

Prednisone has one of the longest and most extensive evidence bases of any medication, reflecting its 70+ years of clinical use since FDA approval in 1955.

Historical Development

Discovery and Approval:

• Prednisone developed as synthetic analog of cortisone
• FDA approved February 21, 1955
• Revolutionized treatment of inflammatory and autoimmune diseases
• Nobel Prize awarded to researchers involved in cortisone/corticosteroid discovery (1950)

Key Clinical Trials and Evidence

Rheumatoid Arthritis:

• Decades of evidence supporting short-term use for flares
• COBRA trial: Early aggressive therapy including prednisone improves long-term outcomes
• Current guidelines recommend low-dose (<10 mg/day) for short periods
• Glucocorticoid-induced remission possible in early RA

Systemic Lupus Erythematosus:

• Standard of care for moderate-severe disease
• Evidence for efficacy in lupus nephritis, CNS lupus, hematologic manifestations
• Combined with immunosuppressants for steroid-sparing effect

Asthma and COPD:

• Extensive evidence for acute exacerbations
• NHLBI Guidelines: 40-60 mg/day for asthma exacerbations
• GOLD Guidelines: 40 mg/day for 5 days for COPD exacerbations
• REDUCE trial (COPD): 5-day course as effective as 14 days

Giant Cell Arteritis/Polymyalgia Rheumatica:

• First-line treatment; dramatic response expected
• Starting doses 12.5-25 mg for PMR; 40-60 mg for GCA
• Long-term studies support prolonged tapered therapy
• Tocilizumab added as steroid-sparing option (GiACTA trial)

Multiple Sclerosis:

• High-dose IV methylprednisolone standard for acute relapses
• Oral prednisone used in follow-up taper
• May hasten recovery but does not alter long-term disease course

Inflammatory Bowel Disease:

• Effective for inducing remission in Crohn's and UC
• Not effective for maintenance (numerous trials)
• Budesonide may be preferred for ileal/right-sided disease

Organ Transplantation:

• Cornerstone of immunosuppressive regimens
• Part of induction and maintenance therapy
• Steroid-sparing/withdrawal protocols increasingly studied

COVID-19 (RECOVERY Trial, 2020):

• Landmark trial demonstrating mortality benefit
• Dexamethasone 6 mg daily reduced mortality in hospitalized patients requiring oxygen
• Prednisone equivalent: ~40 mg daily
• Changed standard of care worldwide

Adverse Effect Evidence

Glucocorticoid-Induced Osteoporosis:

• Well-documented in numerous studies
• ACR Guidelines recommend bone protection for ≥3 months therapy
• Bisphosphonates shown to prevent/treat GIO

Cardiovascular Risk:

• Observational data suggest increased CV events with long-term use
• Dose-dependent relationship
• Confounded by underlying disease activity

Diabetes/Hyperglycemia:

• Strong evidence for dose-dependent hyperglycemia
• New-onset diabetes reported in 2-10% of long-term users
• Worsens control in existing diabetics

Evidence Gaps and Ongoing Research

Optimal Dosing:

• Best doses for specific conditions not always defined
• Tapering protocols often empiric rather than evidence-based

Low-Dose Long-Term:

• Role of very low-dose (≤5 mg) maintenance controversial
• Ongoing studies evaluating risks vs. benefits

Biomarkers:

• No reliable biomarkers to predict individual response
• No way to predict who will develop specific adverse effects

13. Comparison with Alternatives

Corticosteroid Equivalency Table

Prednisone vs. Prednisolone

Prednisone vs. Methylprednisolone

Prednisone vs. Dexamethasone

Prednisone vs. Hydrocortisone

Prednisone vs. Budesonide

Steroid-Sparing Alternatives

For Chronic Inflammatory Conditions:

14. Storage and Handling

Storage Requirements

Immediate-Release Tablets:

• Store at controlled room temperature: 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)
• Protect from moisture
• Keep in original container with tight-fitting lid
• Store away from light

Delayed-Release Tablets (Rayos):

• Store at 25°C (77°F); excursions permitted to 15-30°C
• Keep in original package until use
• Protect from light

Oral Solution:

• Store at controlled room temperature
• Some solutions may require refrigeration (check specific product)
• Use calibrated measuring device
• Discard after expiration date

Stability Considerations

Tablet Stability:

• Generally stable for manufacturer's labeled shelf life (typically 2-3 years)
• Moisture can cause degradation
• Do not use if tablets appear discolored or unusual

Solution Stability:

• Follow specific product guidelines
• Use within labeled time after opening
• Do not freeze

Handling Precautions

Healthcare Provider Handling:

• Standard handling procedures
• No special precautions for intact tablets
• Use appropriate technique for liquid dosing

Patient Handling:

• Take with food to minimize GI upset
• Use measuring device for liquid (not household spoon)
• Do not crush delayed-release tablets
• Keep out of reach of children
• Do not share medication

Dispensing Considerations

Unit-Dose Packaging:

• Available in unit-dose packaging for institutional use
• Helps ensure correct dosing

Dose Packs:

• Medrol Dosepak (methylprednisolone) is common for tapered short courses
• Prednisone dose packs also available
• Provide built-in tapering schedule

Disposal

Proper Disposal:

• Take-back programs preferred
• If unavailable: Mix with undesirable substance (coffee grounds, dirt), place in sealed container, dispose in household trash
• Do not flush tablets
• Remove personal information from containers before disposal

15. References

Primary Literature

1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723.

2. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.

3. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62(11):1515-1526.

4. Moghadam-Kia S, Werth VP. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol. 2010;49(3):239-248.

5. Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833-1838.

Clinical Guidelines

6. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016;68(1):1-25.

7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2024.

8. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122-1128.

9. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol. 2017;69(8):1521-1537.

10. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI). Guidelines for the Diagnosis and Management of Asthma (EPR-3). NIH Publication No. 07-4051. 2007.

Key Trials

11. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693-704.

12. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205-214.

13. Leeb BF, Rintelen B, Galle G, et al. Reduced dosage of the modified-release prednisone formulation in patients with active rheumatoid arthritis (CAPRA-2). Lancet Rheumatol. 2021;3(11):e783-e792.

14. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317-328.

Drug Information Resources

15. Prednisone [package insert]. Various manufacturers.

16. RAYOS (prednisone) delayed-release tablets [package insert]. Horizon Therapeutics.

17. Prednisone. In: Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc.

18. Prednisone. In: AHFS Drug Information. American Society of Health-System Pharmacists.

19. DrugBank Online. Prednisone. https://go.drugbank.com/drugs/DB00635

20. StatPearls [Internet]. Prednisone. National Center for Biotechnology Information.

Pharmacology References

21. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61-98.

22. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19(2):126-146.

23. Pickup ME. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979;4(2):111-128.

24. Tornatore KM, Logue G, Venuto RC, Davis PJ. Pharmacokinetics of methylprednisolone in elderly and young healthy males. J Am Geriatr Soc. 1994;42(10):1118-1122.

25. Tanaka H, Shimizu N, Tougou K, et al. Pharmacokinetics of prednisolone in patients with rheumatoid arthritis and its relation to therapeutic effect. Int J Clin Pharmacol Ther. 1998;36(2):99-104.

16. Goal Archetype Integration

Prednisone serves multiple therapeutic archetypes within clinical practice, each with distinct dosing strategies, monitoring requirements, and outcome expectations.

Corticosteroid Archetype

Primary Classification: Synthetic glucocorticoid with intermediate potency and duration

Physiological Replacement Goals:

• Adrenal insufficiency: Replace missing endogenous cortisol
• Target: Physiological dose of 5-7.5 mg/day (equivalent to ~20 mg hydrocortisone)
• Timing: Morning dosing to mimic circadian cortisol rhythm
• Success Markers: Resolution of fatigue, hypotension, hypoglycemia; normal electrolytes

Supraphysiological Goals:

• Doses >7.5 mg/day exceed physiological replacement
• Intended for pharmacological anti-inflammatory/immunosuppressive effects
• Higher doses = greater efficacy but increased adverse effects
• Always aim for lowest effective dose with defined endpoint

Anti-Inflammatory Archetype

Mechanism Target: Suppress inflammatory cascade at multiple levels

Goal Categories:

Inflammatory Biomarker Goals:

• CRP: Target <1.0 mg/dL (or baseline)
• ESR: Target normalization or >50% reduction
• Joint swelling/effusion: Resolution within 2-4 weeks
• Morning stiffness: <30 minutes duration

Anti-Inflammatory Success Criteria:

1. Symptom relief within 24-72 hours (PMR response often within 24 hours)
2. Laboratory normalization within 1-4 weeks
3. Functional improvement (mobility, ADLs)
4. Ability to taper without flare

Immunosuppression Archetype

Dose-Dependent Immunosuppression:

Immunosuppression Goals by Condition:

Organ Transplantation:

• Prevent acute rejection
• Maintenance: 5-10 mg/day (often tapered to discontinuation)
• Monitor: Rejection episodes, opportunistic infections

Autoimmune Disease:

• Achieve disease remission or low disease activity
• Enable transition to steroid-sparing agents
• Monitor: Disease activity scores, organ function

Hematologic Disorders (ITP, AIHA):

• Platelet count >50,000/mcL (ITP)
• Hemoglobin stabilization (AIHA)
• Duration: Typically 2-4 weeks, then taper

Vaccination Considerations:

• Live vaccines contraindicated at immunosuppressive doses (≥20 mg/day for ≥2 weeks)
• Inactivated vaccines: Administer, but response may be blunted
• Timing: Vaccinate before starting high-dose therapy when possible
• Wait ≥3 months after stopping high-dose therapy before live vaccines

Archetype Selection Framework

Decision Matrix:

17. Age-Stratified Dosing

Prednisone pharmacokinetics and adverse effect profiles vary significantly across age groups, requiring age-specific dosing strategies and monitoring.

Pediatric Population

Pharmacokinetic Differences:

• Faster clearance than adults
• Shorter half-life
• Higher volume of distribution (per kg)
• More pronounced growth effects

Dosing Principles:

• Weight-based dosing (mg/kg/day)
• Maximum doses typically capped at adult equivalents
• Minimize duration to protect growth
• Consider alternate-day therapy when possible

Condition-Specific Pediatric Dosing:

Growth Monitoring Protocol:

• Height velocity every 3-6 months
• Plot on growth charts
• Consider endocrine referral if:
  • Growth velocity <4 cm/year
  • Crossing percentile lines downward
  • Bone age delay >2 years

Pediatric-Specific Adverse Effects:

• Growth suppression (most concerning)
• Behavioral changes (more pronounced than adults)
• Weight gain and obesity
• Adrenal suppression
• Bone mineralization impairment

Adult Population (18-64 years)

Standard Dosing Applies:

• Per condition-specific guidelines
• Consider body weight for high-dose therapy
• Ideal body weight often used for calculations

Gender Considerations:

Women:

• Pregnancy category C (see Special Populations)
• Menstrual irregularities common
• Consider osteoporosis risk earlier (especially if amenorrheic)
• Oral contraceptives increase transcortin (may need dose adjustment)

Men:

• Monitor for hypogonadism with prolonged use
• Testosterone levels may be suppressed
• Fertility effects possible but usually reversible

Geriatric Population (≥65 years)

Physiological Changes Affecting Prednisone:

• Decreased hepatic blood flow (may slow conversion)
• Reduced serum albumin (increased free drug)
• Decreased renal function (minimal effect on PK)
• Reduced bone density at baseline
• Increased cardiovascular risk
• Cognitive vulnerability

Geriatric Dosing Recommendations:

Elderly-Specific Osteoporosis Risk:

The elderly represent the highest-risk population for glucocorticoid-induced osteoporosis (GIOP):

GIOP Prevention Protocol for Elderly:

All patients on ≥2.5 mg/day for ≥3 months:

1. Calcium: 1000-1200 mg/day (diet + supplement)
2. Vitamin D: 800-2000 IU/day (target 25-OH-D >30 ng/mL)
3. DEXA scan at baseline
4. Fall risk assessment
5. Bisphosphonate if:
   • T-score ≤-1.0 at any site
   • Prior fragility fracture
   • FRAX major osteoporotic fracture risk ≥10%
   • Age ≥70 on any GC dose

Bisphosphonate Options:

• Alendronate 70 mg weekly
• Risedronate 35 mg weekly
• Zoledronic acid 5 mg IV annually (preferred if compliance concern)

Denosumab Consideration:

• For bisphosphonate-intolerant patients
• Renal-safe (unlike bisphosphonates)
• 60 mg SC every 6 months

Geriatric-Specific Adverse Effect Surveillance:

Cognitive Effects in Elderly:

• Higher risk of delirium (especially hospital setting)
• Memory impairment more pronounced
• Mood changes (depression more common than euphoria)
• Consider starting lower, particularly for neuropsychiatric risk

18. Drug Interactions - Extended Clinical Integration

Diabetes Medication Interactions

Prednisone significantly impacts glycemic control, necessitating proactive diabetes medication management.

Mechanism of Hyperglycemia:

1. Increased hepatic gluconeogenesis
2. Decreased peripheral glucose uptake
3. Insulin resistance in muscle and fat
4. Impaired insulin secretion
5. Peak effect 4-8 hours post-dose

Interaction with Specific Diabetes Medications:

Insulin Adjustment Protocol:

For patients on basal insulin:

• Morning prednisone: Increase morning NPH or add daytime coverage
• Expect 20-50% increase in total daily dose
• Peak glucose elevation 4-8 hours after prednisone dose

For patients on basal-bolus:

• Increase lunchtime and dinner bolus doses
• May need 50-100% increase in midday insulin
• Consider sliding scale adjustments

New insulin initiation:

• Start with NPH insulin 0.1-0.2 units/kg in morning
• Adjust based on afternoon/evening glucose readings
• Monitor for hypoglycemia during steroid taper

Steroid-Induced Diabetes:

• Screen all patients on ≥20 mg/day for >2 weeks
• New-onset diabetes in 2-10% of patients
• Often resolves with prednisone discontinuation
• May unmask latent diabetes

NSAID Interactions

Combined GI Risk:

Risk Stratification:

High Risk (avoid combination or use maximum protection):

• Age >65
• Prior GI bleed or ulcer
• Concurrent anticoagulant or antiplatelet
• High-dose NSAID or prednisone
• H. pylori positive

Management Strategies:

1. Avoid combination when possible
2. PPI prophylaxis if combination necessary:
   • Omeprazole 20 mg daily
   • Pantoprazole 40 mg daily
   • Esomeprazole 20 mg daily
3. H. pylori testing and treatment before starting
4. COX-2 selective NSAID (lower GI risk but CV concerns)
5. Shortest duration of combination therapy

Cardiovascular Considerations:

• Both increase CV risk independently
• Fluid retention from both agents
• Hypertension exacerbation
• NSAIDs may reduce antihypertensive efficacy

Anticoagulant and Antiplatelet Interactions

Warfarin:

• Variable effect on INR (may increase or decrease)
• Mechanism: Competition for protein binding, altered vitamin K metabolism
• Management: Check INR within 3-7 days of starting/stopping prednisone
• May need 10-20% warfarin dose adjustment

DOACs (Apixaban, Rivaroxaban, etc.):

• Less interaction than warfarin
• No routine monitoring change needed
• Be aware of increased bleeding risk with GI effects

Antiplatelet Agents:

• Aspirin: Prednisone increases aspirin clearance
• Aspirin levels may rise when prednisone stopped (toxicity risk)
• Clopidogrel: No significant pharmacokinetic interaction
• Combined bleeding risk remains

Antihypertensive Interactions

Mechanism of Prednisone-Induced Hypertension:

• Sodium and fluid retention
• Increased vascular sensitivity to catecholamines
• Potassium wasting

Impact on Antihypertensive Classes:

Blood Pressure Goals on Prednisone:

• Target <140/90 mmHg (general population)
• Target <130/80 mmHg (diabetes, CKD, high CV risk)
• More frequent monitoring during therapy
• Expect BP improvement after discontinuation

Psychiatric Medication Interactions

Mood Effects Context:

• Prednisone can cause euphoria, depression, mania, psychosis
• 5-18% experience significant neuropsychiatric effects
• Higher doses = higher risk (especially >40 mg/day)

Interactions:

Steroid Psychosis Management:

• Dose reduction or discontinuation when possible
• Antipsychotic therapy (haloperidol, olanzapine)
• Usually resolves within days of dose reduction
• History of steroid psychosis = higher recurrence risk

19. Bloodwork Impact

Glucose Effects

Pathophysiology:

• Hepatic gluconeogenesis increased
• Peripheral insulin resistance
• Impaired beta-cell function
• Peak effect 4-8 hours post-dose

Expected Laboratory Changes:

Monitoring Protocol:

Short-term therapy (<2 weeks):

• Baseline fasting glucose
• Self-monitoring if diabetic or glucose elevated
• No routine HbA1c needed

Long-term therapy:

• Fasting glucose at baseline, 1 month, then every 3-6 months
• HbA1c every 3 months if glucose elevated
• Consider continuous glucose monitoring in diabetics

Diagnostic Considerations:

• Prednisone elevates glucose; interpret in context
• Do not diagnose new diabetes during high-dose therapy unless persistent
• Re-check glucose 2-4 weeks after discontinuation

Potassium and Electrolyte Effects

Mechanism:

• Mineralocorticoid activity causes renal potassium wasting
• Also causes sodium retention and hydrogen ion loss

Expected Changes:

Monitoring Protocol:

Potassium Replacement:

• Target K+ >4.0 mEq/L (especially if on digoxin)
• Oral supplementation: 20-40 mEq/day typical
• Dietary potassium: Bananas, oranges, potatoes
• Consider potassium-sparing diuretic if persistent hypokalemia

Bone Metabolism Markers

Mechanism of Bone Loss:

• Decreased osteoblast activity (primary mechanism)
• Increased osteoclast activity
• Decreased intestinal calcium absorption
• Increased renal calcium excretion
• Decreased sex hormones
• Muscle wasting (reduces mechanical stress on bone)

Bone Turnover Markers:

Calcium Homeostasis:

Monitoring Protocol for Bone:

Hematologic Effects

Complete Blood Count Changes:

Clinical Interpretation:

• Neutrophilia is expected; do not assume infection
• Lymphopenia is expected; interpret cautiously
• Eosinopenia is characteristic; if eosinophils remain elevated, consider inadequate dosing or other diagnosis
• Infection may present without typical leukocytosis

Lipid Effects

Expected Changes:

Monitoring:

• Baseline lipid panel if long-term therapy expected
• Repeat every 6-12 months
• Manage per cardiovascular risk guidelines
• Statins may be indicated

Adrenal Function Assessment

HPA Axis Suppression:

• Any dose >7.5 mg/day for >3 weeks can suppress
• Morning cortisol is most sensitive screening test
• ACTH stimulation test for definitive assessment

Laboratory Assessment:

When to Test:

• Before final discontinuation of long-term therapy
• If symptoms of adrenal insufficiency during taper
• After prolonged high-dose therapy
• Consider testing at prednisone ~5 mg/day during taper

20. Protocol Integration

Tapering Protocols

Evidence-Based Tapering Principles:

1. No universally validated tapering protocol exists
2. Taper rate depends on dose, duration, and disease
3. Slower tapers for longer treatment durations
4. Monitor for both disease flare and adrenal insufficiency

Short-Course Tapering (<3 weeks):

No taper required if:

• Duration <2 weeks
• No prior chronic steroid use
• Disease permits abrupt stop

Brief taper (optional):

• Reduce by 50% every 3-5 days until stopped
• Example: 40 → 20 → 10 → 5 → stop

Moderate-Duration Tapering (3-8 weeks):

Example starting from 40 mg/day:

Long-Term Therapy Tapering (>3 months):

General approach:

• Above 20 mg: Decrease by 5-10 mg every 1-2 weeks
• 10-20 mg: Decrease by 2.5-5 mg every 2-4 weeks
• 5-10 mg: Decrease by 1-2.5 mg every 2-4 weeks
• Below 5 mg: Decrease by 0.5-1 mg every 2-4 weeks

Example for patient on 20 mg/day for 6 months:

Total taper duration: ~6 months

Disease-Specific Tapering:

Polymyalgia Rheumatica:

• Start: 12.5-25 mg/day
• Initial response within 24-72 hours
• If good response: Taper to 10 mg by 4-8 weeks
• Then reduce by 1 mg every 4-8 weeks
• Total treatment: Often 1-2 years
• Relapse common if tapered too quickly

Giant Cell Arteritis:

• Start: 40-60 mg/day (higher if visual symptoms)
• Maintain 4-6 weeks
• Then taper to 15-20 mg by 3 months
• Slow taper to 10 mg by 6 months
• Continue 1 mg/month reduction to discontinuation
• Total: Often 2+ years
• Consider tocilizumab for steroid-sparing

Inflammatory Bowel Disease:

• Start: 40-60 mg/day
• Maintain until clinical response (1-2 weeks)
• Taper over 8-12 weeks
• Goal: Discontinue; bridge to maintenance therapy
• Do not use for maintenance (ineffective)

HPA Axis Suppression

Risk Factors for Suppression:

• Dose >7.5 mg/day prednisone equivalent
• Duration >3 weeks
• Multiple daily doses (worse than single morning dose)
• Evening dosing (interferes with cortisol nadir)
• Prior adrenal suppression

Clinical Features of Suppression:

During therapy:

• Usually asymptomatic
• May have cushingoid features

During rapid taper or stress:

• Fatigue, weakness
• Hypotension
• Nausea, vomiting, anorexia
• Abdominal pain
• Hypoglycemia
• Hyponatremia
• Eosinophilia (returning)

Adrenal Crisis (Emergency):

• Severe hypotension/shock
• Altered mental status
• Severe abdominal pain
• Fever
• Hypoglycemia

HPA Recovery Timeline:

• Begins when exogenous steroids reduced below physiological
• Full recovery: Weeks to 12+ months
• Average: 6-9 months after discontinuation
• Some patients have prolonged suppression (>1 year)

Management of HPA Suppression:

Prevention:

• Use lowest effective dose
• Single morning dosing when possible
• Alternate-day therapy when feasible
• Taper gradually

Monitoring recovery:

• Morning cortisol at low prednisone doses (~5 mg)
• If <10 mcg/dL: Continue taper slowly
• ACTH stimulation test before final discontinuation
• Normal response: Can complete taper
• Abnormal: May need longer taper or replacement

Stress Dosing Protocol:

Patients on chronic steroids or recently tapered may need "stress doses" during:

• Surgery
• Severe illness/infection
• Trauma
• Other major physiological stress

Stress Dosing Guidelines:

Duration of stress dosing need:

• During active stress
• Taper to baseline over 1-3 days as stress resolves
• Patients may need stress coverage for up to 12 months after stopping chronic steroids

Alternate-Day Therapy Protocol

Rationale:

• Allows HPA axis recovery on off days
• May reduce adrenal suppression
• May reduce some adverse effects
• Maintains therapeutic benefit for some conditions

Conversion Approach:

• Double the daily dose
• Give entire dose every other morning
• Example: 10 mg daily → 20 mg every other morning

Conditions Where Effective:

• Nephrotic syndrome
• Some autoimmune conditions after control achieved
• Asthma (chronic management)
• Rheumatoid arthritis (maintenance)

Conditions Where Less Effective:

• Conditions requiring constant suppression
• Active organ transplant rejection risk
• Acute disease flares
• Some patients: Disease flares on off days

Limitations:

• Symptom breakthrough on off days possible
• Not all patients tolerate
• May not prevent all adverse effects
• Limited evidence base

Integration with Steroid-Sparing Agents

Rationale for Steroid-Sparing:

• Reduce cumulative steroid exposure
• Minimize long-term adverse effects
• Improve disease control
• Enable steroid discontinuation

Common Steroid-Sparing Strategies:

Steroid-Sparing Protocol Example (RA):

Monitoring During Protocol Transitions

During Taper:

• Disease activity assessment at each dose change
• Symptoms of adrenal insufficiency
• Morning cortisol when approaching physiological doses

Flare Management:

• Increase to last effective dose
• Slower subsequent taper
• Re-evaluate steroid-sparing therapy
• May need additional steroid-sparing agent

Red Flags Requiring Immediate Attention:

• Symptoms of adrenal crisis
• Severe disease flare
• Intercurrent illness (may need stress dosing)
• Significant mood changes

Document Footer

Document Completion: 2025-12-26 Last Enhanced: 2026-01-05 Status: PAPER 49 OF 76 COMPLETE Next Paper: #50 - Prednisolone

Clinical Notes: Prednisone remains a cornerstone medication for numerous inflammatory, autoimmune, and neoplastic conditions. Its low cost and wide availability make it accessible worldwide. However, the significant adverse effect profile, particularly with long-term use, necessitates careful patient selection, use of the lowest effective dose, and comprehensive monitoring. Steroid-sparing strategies should be employed whenever possible.

Enhancement Notes: This paper has been expanded with five additional sections covering Goal Archetype Integration (corticosteroid, anti-inflammatory, immunosuppression frameworks), Age-Stratified Dosing with particular attention to elderly osteoporosis risk, Extended Drug Interactions (diabetes medications, NSAIDs, antihypertensives), Bloodwork Impact (glucose, electrolytes, bone markers, hematologic effects), and Protocol Integration (tapering protocols, HPA axis suppression management, alternate-day therapy).

This research paper is part of a comprehensive HRT/hormone product documentation project for Epiq Aminos clinical reference materials.